Managing Spectral Interferences Using Optical Coagulation Methods Article Swipe
Kendall W Cradic
,
Chris Rosemark
,
Darci R Block
,
N Baumann
·
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1093/ajcp/aqy112.355
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1093/ajcp/aqy112.355
Both mechanical and optical-based methods are available for measuring prothrombin time (PT) and activated partial thromboplastin time (aPTT). When optical methods are used, interference from hemolysis, lipemia, and icterus is a concern. Hemolysis is generally resolved by re-collection of the specimen. Lipemia and icterus, however, are problematic because laboratory mitigation procedures such as sample dilution cannot be performed for PT and aPTT. Processes for handling these interferences and providing accurate results are needed. The objective of this study was to develop mitigation strategies for lipemic and icteric specimens submitted for PT and aPTT testing using an optical platform. Our aims were to (1) validate centrifugation for reducing lipemia and (2) characterize the magnitude of interference caused by elevated bilirubin. The proportion of samples received in the laboratory with significant lipemia and icterus was estimated based on retrospective analysis of over 6,000 specimens. PT and aPTT were measured using the ACL TOP700 (Instrumentation Laboratories, Bedford, MA). Icterus and lipemia were quantified using serum indices (I-index and L-index, respectively) on the Roche c701 analyzer (Roche Diagnostics, Indianapolis, IN). Residual lipemic plasma samples (L-index 2–129, n = 10) were assayed (PT, aPTT) before and after centrifugation at 12,000g for 5 minutes (Pico, Thermo Scientific). To evaluate the effect of icterus, residual specimens with results ranging from normal to prolonged (PT = 12–52 seconds; n = 6) (aPTT = 32–63 seconds; n = 7) were obtained. Each specimen was divided into two aliquots and either diluent or bilirubin (final concentration 60 mg/dL) (Calbiochem) was added. Admixtures of the two fractions were made to create a series of samples with increasing bilirubin concentrations. Mean percent difference (mean(range)) in PT and aPTT results with increasing bilirubin concentrations were calculated. Approximately 0.01% and 0.1% of specimens received for PT and aPTT testing were lipemic and icteric, respectively. Among lipemic specimens, centrifugation reduced the L-index by 68% (34%-90%) (mean (range)) while altering PT and aPTT by –1.2% (–2.5% to 0.0%) and 0.0% (–4.9% to 4.5%), respectively. At the manufacturer’s package insert thresholds for bilirubin, PT (I-index = 40) and aPTT (I-index = 35) were prolonged by 4% (1%-11%) and 4% (0%-9%), respectively. At an I-index of 50, false prolongation was 10% (5%-20%) for PT and 12% (5%-22%) for aPTT. Very high bilirubin concentrations (I-index = 60, bilirubin = 45 mg/dL) caused false prolongation of 18% (11%-27%) for PT and 22% (9%-30%) for aPTT. Lipemic and icteric specimens are not common but present challenges for laboratories using optical coagulation methods for PT and aPTT. Lipemia caused minimal interference and was resolved by centrifugation. Icterus was a significant interferent when bilirubin was >26 mg/dL. The impact of icterus on PT and aPTT can be estimated and provided as an interpretive comment allowing assessment of liver function and coagulation status in patients with elevated bilirubin concentrations.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/ajcp/aqy112.355
- https://academic.oup.com/ajcp/article-pdf/150/suppl_1/S150/25805840/aqy112.355.pdf
- OA Status
- bronze
- Cited By
- 2
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2891830686
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2891830686Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/ajcp/aqy112.355Digital Object Identifier
- Title
-
Managing Spectral Interferences Using Optical Coagulation MethodsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2018Year of publication
- Publication date
-
2018-09-21Full publication date if available
- Authors
-
Kendall W Cradic, Chris Rosemark, Darci R Block, N BaumannList of authors in order
- Landing page
-
https://doi.org/10.1093/ajcp/aqy112.355Publisher landing page
- PDF URL
-
https://academic.oup.com/ajcp/article-pdf/150/suppl_1/S150/25805840/aqy112.355.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/ajcp/article-pdf/150/suppl_1/S150/25805840/aqy112.355.pdfDirect OA link when available
- Concepts
-
Partial thromboplastin time, Hemolysis, Prothrombin time, Chromatography, Bilirubin, Chemistry, Coagulation testing, Centrifugation, Coagulation, Medicine, Gastroenterology, Internal medicineTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
2Total citation count in OpenAlex
- Citations by year (recent)
-
2022: 2Per-year citation counts (last 5 years)
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2891830686 |
|---|---|
| doi | https://doi.org/10.1093/ajcp/aqy112.355 |
| ids.doi | https://doi.org/10.1093/ajcp/aqy112.355 |
| ids.mag | 2891830686 |
| ids.openalex | https://openalex.org/W2891830686 |
| fwci | 0.0 |
| type | article |
| title | Managing Spectral Interferences Using Optical Coagulation Methods |
| biblio.issue | suppl_1 |
| biblio.volume | 150 |
| biblio.last_page | S151 |
| biblio.first_page | S150 |
| topics[0].id | https://openalex.org/T11314 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9984999895095825 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2737 |
| topics[0].subfield.display_name | Physiology |
| topics[0].display_name | Clinical Laboratory Practices and Quality Control |
| topics[1].id | https://openalex.org/T10218 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9918000102043152 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2713 |
| topics[1].subfield.display_name | Epidemiology |
| topics[1].display_name | Sepsis Diagnosis and Treatment |
| topics[2].id | https://openalex.org/T10285 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.984499990940094 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2724 |
| topics[2].subfield.display_name | Internal Medicine |
| topics[2].display_name | Venous Thromboembolism Diagnosis and Management |
| is_xpac | False |
| apc_list.value | 4440 |
| apc_list.currency | USD |
| apc_list.value_usd | 4440 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2778261982 |
| concepts[0].level | 3 |
| concepts[0].score | 0.7313766479492188 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q1755136 |
| concepts[0].display_name | Partial thromboplastin time |
| concepts[1].id | https://openalex.org/C2779902561 |
| concepts[1].level | 2 |
| concepts[1].score | 0.6224628686904907 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q471706 |
| concepts[1].display_name | Hemolysis |
| concepts[2].id | https://openalex.org/C2780434524 |
| concepts[2].level | 2 |
| concepts[2].score | 0.6137908101081848 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q1144385 |
| concepts[2].display_name | Prothrombin time |
| concepts[3].id | https://openalex.org/C43617362 |
| concepts[3].level | 1 |
| concepts[3].score | 0.6075965166091919 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q170050 |
| concepts[3].display_name | Chromatography |
| concepts[4].id | https://openalex.org/C2777513400 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5477057695388794 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q104219 |
| concepts[4].display_name | Bilirubin |
| concepts[5].id | https://openalex.org/C185592680 |
| concepts[5].level | 0 |
| concepts[5].score | 0.5263546705245972 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[5].display_name | Chemistry |
| concepts[6].id | https://openalex.org/C16124881 |
| concepts[6].level | 3 |
| concepts[6].score | 0.49750950932502747 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q5363933 |
| concepts[6].display_name | Coagulation testing |
| concepts[7].id | https://openalex.org/C7623868 |
| concepts[7].level | 2 |
| concepts[7].score | 0.44710052013397217 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1967135 |
| concepts[7].display_name | Centrifugation |
| concepts[8].id | https://openalex.org/C2778382381 |
| concepts[8].level | 2 |
| concepts[8].score | 0.36195701360702515 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q179217 |
| concepts[8].display_name | Coagulation |
| concepts[9].id | https://openalex.org/C71924100 |
| concepts[9].level | 0 |
| concepts[9].score | 0.3351755142211914 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[9].display_name | Medicine |
| concepts[10].id | https://openalex.org/C90924648 |
| concepts[10].level | 1 |
| concepts[10].score | 0.24236705899238586 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[10].display_name | Gastroenterology |
| concepts[11].id | https://openalex.org/C126322002 |
| concepts[11].level | 1 |
| concepts[11].score | 0.19514387845993042 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[11].display_name | Internal medicine |
| keywords[0].id | https://openalex.org/keywords/partial-thromboplastin-time |
| keywords[0].score | 0.7313766479492188 |
| keywords[0].display_name | Partial thromboplastin time |
| keywords[1].id | https://openalex.org/keywords/hemolysis |
| keywords[1].score | 0.6224628686904907 |
| keywords[1].display_name | Hemolysis |
| keywords[2].id | https://openalex.org/keywords/prothrombin-time |
| keywords[2].score | 0.6137908101081848 |
| keywords[2].display_name | Prothrombin time |
| keywords[3].id | https://openalex.org/keywords/chromatography |
| keywords[3].score | 0.6075965166091919 |
| keywords[3].display_name | Chromatography |
| keywords[4].id | https://openalex.org/keywords/bilirubin |
| keywords[4].score | 0.5477057695388794 |
| keywords[4].display_name | Bilirubin |
| keywords[5].id | https://openalex.org/keywords/chemistry |
| keywords[5].score | 0.5263546705245972 |
| keywords[5].display_name | Chemistry |
| keywords[6].id | https://openalex.org/keywords/coagulation-testing |
| keywords[6].score | 0.49750950932502747 |
| keywords[6].display_name | Coagulation testing |
| keywords[7].id | https://openalex.org/keywords/centrifugation |
| keywords[7].score | 0.44710052013397217 |
| keywords[7].display_name | Centrifugation |
| keywords[8].id | https://openalex.org/keywords/coagulation |
| keywords[8].score | 0.36195701360702515 |
| keywords[8].display_name | Coagulation |
| keywords[9].id | https://openalex.org/keywords/medicine |
| keywords[9].score | 0.3351755142211914 |
| keywords[9].display_name | Medicine |
| keywords[10].id | https://openalex.org/keywords/gastroenterology |
| keywords[10].score | 0.24236705899238586 |
| keywords[10].display_name | Gastroenterology |
| keywords[11].id | https://openalex.org/keywords/internal-medicine |
| keywords[11].score | 0.19514387845993042 |
| keywords[11].display_name | Internal medicine |
| language | en |
| locations[0].id | doi:10.1093/ajcp/aqy112.355 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S15871148 |
| locations[0].source.issn | 0002-9173, 1943-7722 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0002-9173 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | American Journal of Clinical Pathology |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| locations[0].source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| locations[0].license | |
| locations[0].pdf_url | https://academic.oup.com/ajcp/article-pdf/150/suppl_1/S150/25805840/aqy112.355.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | American Journal of Clinical Pathology |
| locations[0].landing_page_url | https://doi.org/10.1093/ajcp/aqy112.355 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5006845192 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Kendall W Cradic |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210125099 |
| authorships[0].affiliations[0].raw_affiliation_string | Mayo Clinic, Rochester, MN |
| authorships[0].institutions[0].id | https://openalex.org/I4210125099 |
| authorships[0].institutions[0].ror | https://ror.org/03jp40720 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I1330342723, https://openalex.org/I4210125099 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Mayo Clinic in Arizona |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Kendall Cradic |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Mayo Clinic, Rochester, MN |
| authorships[1].author.id | https://openalex.org/A5035117835 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Chris Rosemark |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210125099 |
| authorships[1].affiliations[0].raw_affiliation_string | Mayo Clinic, Rochester, MN |
| authorships[1].institutions[0].id | https://openalex.org/I4210125099 |
| authorships[1].institutions[0].ror | https://ror.org/03jp40720 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I1330342723, https://openalex.org/I4210125099 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Mayo Clinic in Arizona |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Chris Rosemark |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Mayo Clinic, Rochester, MN |
| authorships[2].author.id | https://openalex.org/A5036578577 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-2130-3372 |
| authorships[2].author.display_name | Darci R Block |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210125099 |
| authorships[2].affiliations[0].raw_affiliation_string | Mayo Clinic, Rochester, MN |
| authorships[2].institutions[0].id | https://openalex.org/I4210125099 |
| authorships[2].institutions[0].ror | https://ror.org/03jp40720 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I1330342723, https://openalex.org/I4210125099 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Mayo Clinic in Arizona |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Darci Block |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Mayo Clinic, Rochester, MN |
| authorships[3].author.id | https://openalex.org/A5012070961 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | N Baumann |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210125099 |
| authorships[3].affiliations[0].raw_affiliation_string | Mayo Clinic, Rochester, MN |
| authorships[3].institutions[0].id | https://openalex.org/I4210125099 |
| authorships[3].institutions[0].ror | https://ror.org/03jp40720 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I1330342723, https://openalex.org/I4210125099 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Mayo Clinic in Arizona |
| authorships[3].author_position | last |
| authorships[3].raw_author_name | Nikola Baumann |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Mayo Clinic, Rochester, MN |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/ajcp/article-pdf/150/suppl_1/S150/25805840/aqy112.355.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Managing Spectral Interferences Using Optical Coagulation Methods |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11314 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9984999895095825 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2737 |
| primary_topic.subfield.display_name | Physiology |
| primary_topic.display_name | Clinical Laboratory Practices and Quality Control |
| related_works | https://openalex.org/W2066960350, https://openalex.org/W2379432586, https://openalex.org/W2132634835, https://openalex.org/W1991078228, https://openalex.org/W1980182349, https://openalex.org/W2436655773, https://openalex.org/W25265712, https://openalex.org/W2107023801, https://openalex.org/W2131472342, https://openalex.org/W3117397403 |
| cited_by_count | 2 |
| counts_by_year[0].year | 2022 |
| counts_by_year[0].cited_by_count | 2 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1093/ajcp/aqy112.355 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S15871148 |
| best_oa_location.source.issn | 0002-9173, 1943-7722 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0002-9173 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | American Journal of Clinical Pathology |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| best_oa_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://academic.oup.com/ajcp/article-pdf/150/suppl_1/S150/25805840/aqy112.355.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | American Journal of Clinical Pathology |
| best_oa_location.landing_page_url | https://doi.org/10.1093/ajcp/aqy112.355 |
| primary_location.id | doi:10.1093/ajcp/aqy112.355 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S15871148 |
| primary_location.source.issn | 0002-9173, 1943-7722 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0002-9173 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | American Journal of Clinical Pathology |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| primary_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| primary_location.license | |
| primary_location.pdf_url | https://academic.oup.com/ajcp/article-pdf/150/suppl_1/S150/25805840/aqy112.355.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | American Journal of Clinical Pathology |
| primary_location.landing_page_url | https://doi.org/10.1093/ajcp/aqy112.355 |
| publication_date | 2018-09-21 |
| publication_year | 2018 |
| referenced_works_count | 0 |
| abstract_inverted_index.5 | 196 |
| abstract_inverted_index.= | 183, 217, 221, 224, 228, 338, 343, 376, 379 |
| abstract_inverted_index.a | 30, 260, 426 |
| abstract_inverted_index.n | 182, 220, 227 |
| abstract_inverted_index.4% | 348, 351 |
| abstract_inverted_index.45 | 380 |
| abstract_inverted_index.6) | 222 |
| abstract_inverted_index.60 | 246 |
| abstract_inverted_index.7) | 229 |
| abstract_inverted_index.At | 328, 354 |
| abstract_inverted_index.PT | 59, 90, 142, 273, 291, 314, 336, 365, 389, 412, 439 |
| abstract_inverted_index.To | 201 |
| abstract_inverted_index.an | 95, 355, 448 |
| abstract_inverted_index.as | 52, 447 |
| abstract_inverted_index.at | 193 |
| abstract_inverted_index.be | 56, 443 |
| abstract_inverted_index.by | 36, 116, 307, 317, 347, 422 |
| abstract_inverted_index.in | 124, 272, 459 |
| abstract_inverted_index.is | 29, 33 |
| abstract_inverted_index.of | 38, 75, 113, 121, 138, 205, 252, 262, 287, 357, 385, 436, 453 |
| abstract_inverted_index.on | 135, 167, 438 |
| abstract_inverted_index.or | 242 |
| abstract_inverted_index.to | 79, 101, 214, 258, 320, 325 |
| abstract_inverted_index.(1) | 102 |
| abstract_inverted_index.(2) | 109 |
| abstract_inverted_index.(PT | 216 |
| abstract_inverted_index.10% | 362 |
| abstract_inverted_index.10) | 184 |
| abstract_inverted_index.12% | 367 |
| abstract_inverted_index.18% | 386 |
| abstract_inverted_index.22% | 391 |
| abstract_inverted_index.35) | 344 |
| abstract_inverted_index.40) | 339 |
| abstract_inverted_index.50, | 358 |
| abstract_inverted_index.60, | 377 |
| abstract_inverted_index.68% | 308 |
| abstract_inverted_index.>26 | 432 |
| abstract_inverted_index.ACL | 149 |
| abstract_inverted_index.Our | 98 |
| abstract_inverted_index.The | 73, 119, 434 |
| abstract_inverted_index.and | 2, 12, 27, 42, 60, 67, 85, 91, 108, 130, 143, 156, 164, 190, 239, 274, 285, 292, 297, 315, 322, 340, 350, 366, 390, 396, 413, 419, 440, 445, 456 |
| abstract_inverted_index.are | 5, 21, 45, 71, 399 |
| abstract_inverted_index.but | 402 |
| abstract_inverted_index.can | 442 |
| abstract_inverted_index.for | 7, 58, 63, 83, 89, 105, 195, 290, 334, 364, 369, 388, 393, 405, 411 |
| abstract_inverted_index.not | 400 |
| abstract_inverted_index.the | 39, 111, 125, 148, 168, 203, 253, 305, 329 |
| abstract_inverted_index.two | 237, 254 |
| abstract_inverted_index.was | 78, 132, 234, 249, 361, 420, 425, 431 |
| abstract_inverted_index.(PT) | 11 |
| abstract_inverted_index.(PT, | 187 |
| abstract_inverted_index.0.0% | 323 |
| abstract_inverted_index.0.1% | 286 |
| abstract_inverted_index.Both | 0 |
| abstract_inverted_index.Each | 232 |
| abstract_inverted_index.IN). | 175 |
| abstract_inverted_index.MA). | 154 |
| abstract_inverted_index.Mean | 268 |
| abstract_inverted_index.Very | 371 |
| abstract_inverted_index.When | 18 |
| abstract_inverted_index.aPTT | 92, 144, 275, 293, 316, 341, 441 |
| abstract_inverted_index.aims | 99 |
| abstract_inverted_index.c701 | 170 |
| abstract_inverted_index.from | 24, 212 |
| abstract_inverted_index.high | 372 |
| abstract_inverted_index.into | 236 |
| abstract_inverted_index.made | 257 |
| abstract_inverted_index.over | 139 |
| abstract_inverted_index.such | 51 |
| abstract_inverted_index.this | 76 |
| abstract_inverted_index.time | 10, 16 |
| abstract_inverted_index.were | 100, 145, 158, 185, 230, 256, 281, 295, 345 |
| abstract_inverted_index.when | 429 |
| abstract_inverted_index.with | 127, 209, 264, 277, 461 |
| abstract_inverted_index.(aPTT | 223 |
| abstract_inverted_index.(mean | 310 |
| abstract_inverted_index.0.0%) | 321 |
| abstract_inverted_index.0.01% | 284 |
| abstract_inverted_index.6,000 | 140 |
| abstract_inverted_index.Among | 300 |
| abstract_inverted_index.Roche | 169 |
| abstract_inverted_index.aPTT) | 188 |
| abstract_inverted_index.aPTT. | 61, 370, 394, 414 |
| abstract_inverted_index.after | 191 |
| abstract_inverted_index.based | 134 |
| abstract_inverted_index.false | 359, 383 |
| abstract_inverted_index.liver | 454 |
| abstract_inverted_index.serum | 161 |
| abstract_inverted_index.study | 77 |
| abstract_inverted_index.these | 65 |
| abstract_inverted_index.used, | 22 |
| abstract_inverted_index.using | 94, 147, 160, 407 |
| abstract_inverted_index.while | 312 |
| abstract_inverted_index.(Pico, | 198 |
| abstract_inverted_index.(Roche | 172 |
| abstract_inverted_index.(final | 244 |
| abstract_inverted_index.4.5%), | 326 |
| abstract_inverted_index.TOP700 | 150 |
| abstract_inverted_index.Thermo | 199 |
| abstract_inverted_index.added. | 250 |
| abstract_inverted_index.before | 189 |
| abstract_inverted_index.cannot | 55 |
| abstract_inverted_index.caused | 115, 382, 416 |
| abstract_inverted_index.common | 401 |
| abstract_inverted_index.create | 259 |
| abstract_inverted_index.effect | 204 |
| abstract_inverted_index.either | 240 |
| abstract_inverted_index.impact | 435 |
| abstract_inverted_index.insert | 332 |
| abstract_inverted_index.mg/dL) | 247, 381 |
| abstract_inverted_index.mg/dL. | 433 |
| abstract_inverted_index.normal | 213 |
| abstract_inverted_index.plasma | 178 |
| abstract_inverted_index.sample | 53 |
| abstract_inverted_index.series | 261 |
| abstract_inverted_index.status | 458 |
| abstract_inverted_index.(aPTT). | 17 |
| abstract_inverted_index.12,000g | 194 |
| abstract_inverted_index.12–52 | 218 |
| abstract_inverted_index.32–63 | 225 |
| abstract_inverted_index.I-index | 356 |
| abstract_inverted_index.Icterus | 155, 424 |
| abstract_inverted_index.L-index | 306 |
| abstract_inverted_index.Lipemia | 41, 415 |
| abstract_inverted_index.Lipemic | 395 |
| abstract_inverted_index.assayed | 186 |
| abstract_inverted_index.because | 47 |
| abstract_inverted_index.comment | 450 |
| abstract_inverted_index.develop | 80 |
| abstract_inverted_index.diluent | 241 |
| abstract_inverted_index.divided | 235 |
| abstract_inverted_index.icteric | 86, 397 |
| abstract_inverted_index.icterus | 28, 131, 437 |
| abstract_inverted_index.indices | 162 |
| abstract_inverted_index.lipemia | 107, 129, 157 |
| abstract_inverted_index.lipemic | 84, 177, 296, 301 |
| abstract_inverted_index.methods | 4, 20, 410 |
| abstract_inverted_index.minimal | 417 |
| abstract_inverted_index.minutes | 197 |
| abstract_inverted_index.needed. | 72 |
| abstract_inverted_index.optical | 19, 96, 408 |
| abstract_inverted_index.package | 331 |
| abstract_inverted_index.partial | 14 |
| abstract_inverted_index.percent | 269 |
| abstract_inverted_index.present | 403 |
| abstract_inverted_index.ranging | 211 |
| abstract_inverted_index.reduced | 304 |
| abstract_inverted_index.results | 70, 210, 276 |
| abstract_inverted_index.samples | 122, 179, 263 |
| abstract_inverted_index.testing | 93, 294 |
| abstract_inverted_index.–1.2% | 318 |
| abstract_inverted_index.(0%-9%), | 352 |
| abstract_inverted_index.(1%-11%) | 349 |
| abstract_inverted_index.(5%-20%) | 363 |
| abstract_inverted_index.(5%-22%) | 368 |
| abstract_inverted_index.(9%-30%) | 392 |
| abstract_inverted_index.(I-index | 163, 337, 342, 375 |
| abstract_inverted_index.(L-index | 180 |
| abstract_inverted_index.(range)) | 311 |
| abstract_inverted_index.(–2.5% | 319 |
| abstract_inverted_index.(–4.9% | 324 |
| abstract_inverted_index.2–129, | 181 |
| abstract_inverted_index.Bedford, | 153 |
| abstract_inverted_index.L-index, | 165 |
| abstract_inverted_index.Residual | 176 |
| abstract_inverted_index.accurate | 69 |
| abstract_inverted_index.aliquots | 238 |
| abstract_inverted_index.allowing | 451 |
| abstract_inverted_index.altering | 313 |
| abstract_inverted_index.analysis | 137 |
| abstract_inverted_index.analyzer | 171 |
| abstract_inverted_index.concern. | 31 |
| abstract_inverted_index.dilution | 54 |
| abstract_inverted_index.elevated | 117, 462 |
| abstract_inverted_index.evaluate | 202 |
| abstract_inverted_index.function | 455 |
| abstract_inverted_index.handling | 64 |
| abstract_inverted_index.however, | 44 |
| abstract_inverted_index.icteric, | 298 |
| abstract_inverted_index.icterus, | 43, 206 |
| abstract_inverted_index.lipemia, | 26 |
| abstract_inverted_index.measured | 146 |
| abstract_inverted_index.patients | 460 |
| abstract_inverted_index.provided | 446 |
| abstract_inverted_index.received | 123, 289 |
| abstract_inverted_index.reducing | 106 |
| abstract_inverted_index.residual | 207 |
| abstract_inverted_index.resolved | 35, 421 |
| abstract_inverted_index.seconds; | 219, 226 |
| abstract_inverted_index.specimen | 233 |
| abstract_inverted_index.validate | 103 |
| abstract_inverted_index.(11%-27%) | 387 |
| abstract_inverted_index.(34%-90%) | 309 |
| abstract_inverted_index.Hemolysis | 32 |
| abstract_inverted_index.Processes | 62 |
| abstract_inverted_index.activated | 13 |
| abstract_inverted_index.available | 6 |
| abstract_inverted_index.bilirubin | 243, 266, 279, 373, 378, 430, 463 |
| abstract_inverted_index.estimated | 133, 444 |
| abstract_inverted_index.fractions | 255 |
| abstract_inverted_index.generally | 34 |
| abstract_inverted_index.magnitude | 112 |
| abstract_inverted_index.measuring | 8 |
| abstract_inverted_index.objective | 74 |
| abstract_inverted_index.obtained. | 231 |
| abstract_inverted_index.performed | 57 |
| abstract_inverted_index.platform. | 97 |
| abstract_inverted_index.prolonged | 215, 346 |
| abstract_inverted_index.providing | 68 |
| abstract_inverted_index.specimen. | 40 |
| abstract_inverted_index.specimens | 87, 208, 288, 398 |
| abstract_inverted_index.submitted | 88 |
| abstract_inverted_index.Admixtures | 251 |
| abstract_inverted_index.assessment | 452 |
| abstract_inverted_index.bilirubin, | 335 |
| abstract_inverted_index.bilirubin. | 118 |
| abstract_inverted_index.challenges | 404 |
| abstract_inverted_index.difference | 270 |
| abstract_inverted_index.hemolysis, | 25 |
| abstract_inverted_index.increasing | 265, 278 |
| abstract_inverted_index.laboratory | 48, 126 |
| abstract_inverted_index.mechanical | 1 |
| abstract_inverted_index.mitigation | 49, 81 |
| abstract_inverted_index.procedures | 50 |
| abstract_inverted_index.proportion | 120 |
| abstract_inverted_index.quantified | 159 |
| abstract_inverted_index.specimens, | 302 |
| abstract_inverted_index.specimens. | 141 |
| abstract_inverted_index.strategies | 82 |
| abstract_inverted_index.thresholds | 333 |
| abstract_inverted_index.calculated. | 282 |
| abstract_inverted_index.coagulation | 409, 457 |
| abstract_inverted_index.interferent | 428 |
| abstract_inverted_index.problematic | 46 |
| abstract_inverted_index.prothrombin | 9 |
| abstract_inverted_index.significant | 128, 427 |
| abstract_inverted_index.(Calbiochem) | 248 |
| abstract_inverted_index.Diagnostics, | 173 |
| abstract_inverted_index.Scientific). | 200 |
| abstract_inverted_index.characterize | 110 |
| abstract_inverted_index.interference | 23, 114, 418 |
| abstract_inverted_index.interpretive | 449 |
| abstract_inverted_index.laboratories | 406 |
| abstract_inverted_index.prolongation | 360, 384 |
| abstract_inverted_index.(mean(range)) | 271 |
| abstract_inverted_index.Approximately | 283 |
| abstract_inverted_index.Indianapolis, | 174 |
| abstract_inverted_index.Laboratories, | 152 |
| abstract_inverted_index.concentration | 245 |
| abstract_inverted_index.interferences | 66 |
| abstract_inverted_index.optical-based | 3 |
| abstract_inverted_index.re-collection | 37 |
| abstract_inverted_index.respectively) | 166 |
| abstract_inverted_index.respectively. | 299, 327, 353 |
| abstract_inverted_index.retrospective | 136 |
| abstract_inverted_index.centrifugation | 104, 192, 303 |
| abstract_inverted_index.concentrations | 280, 374 |
| abstract_inverted_index.thromboplastin | 15 |
| abstract_inverted_index.centrifugation. | 423 |
| abstract_inverted_index.concentrations. | 267, 464 |
| abstract_inverted_index.(Instrumentation | 151 |
| abstract_inverted_index.manufacturer’s | 330 |
| cited_by_percentile_year.max | 96 |
| cited_by_percentile_year.min | 94 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 4 |
| citation_normalized_percentile.value | 0.13933574 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |